| abstract |
An anti-GDF15 antibody is provided. Monoclonal antibodies that bind to human GDF15 and inhibit its activity are disclosed. This antibody can be used to treat weight loss, including cachexia, associated with overexpression of human GDF15. The present invention is based in part on the discovery of a family of antibodies that specifically bind to human GDF15 (hGDF15). These antibodies contain an hGDF15 binding site based on the CDRs of the antibody. These antibodies can be used as therapeutic agents. When used as therapeutic agents, these antibodies have been modified, eg, humanized, to reduce or eliminate the immune response when administered to a human patient. [Selection figure] None |